ESA is the standard of care for CKD patients with anemia, despite being associated with several life-threatening adverse events, such as hypertension, thromboembolism, stroke, myocardial infarction, and mortality, particularly above the target Hb range. This evidence concerns the gene GSTM1 and Hypertension.